Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Merck Sharp & Dohme (MSD)

Status: Terminated

Conditions: Hepatitis C, Chronic; Hepacivirus

Treatments: Drug: Ribavirin (SCH 18908); Behavioral: Patient assistance program; Biological: Peginterferon alfa-2b (SCH 54031)

Study type: Observational

Funder types: Industry

Identifiers

NCT00723879

P04206

Details and patient eligibility

About

Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron and Rebetol (according to the label) and the patient assistance program, which includes (1) medications used for treatment (psychiatric medications); (2) other interventions (nurse support); and (3) educational literature. This study will be compared to similar studies from other clinics using various patient support programs for the purpose of designing future comparative phase IV studies.

Enrollment: 115 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic hepatitis C naive to treatment

Exclusion criteria

• None

Trial design

115 participants in 1 patient group

Patients with hepatitis C

Description:

Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.

Treatment:

Behavioral: Patient assistance program

Biological: Peginterferon alfa-2b (SCH 54031)

Drug: Ribavirin (SCH 18908)